Therapeutic delivery with V-amylose
© 2021 Wiley Periodicals, LLC..
The helical structure of V-amylose offering a superior encapsulation affinity compared with the other polysaccharides, especially toward the amphiphilic or hydrophobic molecules; in addition to providing a higher resistance toward enzymatic hydrolysis support its applications as a potential drug delivery vehicle. Mainly, the glycosidic linkages and -CH2 - groups forming the hydrophobic cavity of V-amylose helix, and the glycosyl hydroxyl groups constituting its hydrophilic periphery promote the loading of a diverse range of molecules via van der Waals forces and hydrogen bonding interactions. These properties enable a high-loading efficiency, targeted delivery, and controlled release of the cargo drug molecules by V-amylose. Besides, V-amylose presents characteristics of an ideal drug delivery system, such as biocompatibility, physiological benevolence, nonimmunogenicity, and biodegradability. The V-amylose polysaccharide chains fold into left-handed single helix comprising of six glucose units in each turn having a pitch height of 7.91-8.17 Å. These structural features of V-amylose differentiate it from the parent amylose polysaccharide and enable the accommodation and nanoencapsulation of a wide range of therapeutics in the former. The tightly packed helical structure of V-amylose provides extraordinary resistance toward digestion by amylase compared with the linear polysaccharides, which supports the application of V-amylose as controlled drug release systems. The activity of the amylase enzyme produced by salivary glands, pancreas, gastrointestinal tract, and gut microbiota on amylose-based drug delivery vehicles promote enzyme-sensitive controlled oral and colon-specific release of the encapsulated drug. The single helical V-amylose with hydrophobic core and hydrophilic periphery forms inclusion complexes that improve the absorption and permeation of drugs having a high clogP index. The present commentary highlights the distinguished features of V-amylose as an imminent drug delivery system.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:82 |
---|---|
Enthalten in: |
Drug development research - 82(2021), 6 vom: 15. Sept., Seite 727-729 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Prasher, Parteek [VerfasserIn] |
---|
Links: |
---|
Themen: |
9005-82-7 |
---|
Anmerkungen: |
Date Completed 04.04.2022 Date Revised 05.04.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/ddr.21804 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM321458176 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM321458176 | ||
003 | DE-627 | ||
005 | 20231225175840.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/ddr.21804 |2 doi | |
028 | 5 | 2 | |a pubmed24n1071.xml |
035 | |a (DE-627)NLM321458176 | ||
035 | |a (NLM)33586190 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Prasher, Parteek |e verfasserin |4 aut | |
245 | 1 | 0 | |a Therapeutic delivery with V-amylose |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 04.04.2022 | ||
500 | |a Date Revised 05.04.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021 Wiley Periodicals, LLC. | ||
520 | |a The helical structure of V-amylose offering a superior encapsulation affinity compared with the other polysaccharides, especially toward the amphiphilic or hydrophobic molecules; in addition to providing a higher resistance toward enzymatic hydrolysis support its applications as a potential drug delivery vehicle. Mainly, the glycosidic linkages and -CH2 - groups forming the hydrophobic cavity of V-amylose helix, and the glycosyl hydroxyl groups constituting its hydrophilic periphery promote the loading of a diverse range of molecules via van der Waals forces and hydrogen bonding interactions. These properties enable a high-loading efficiency, targeted delivery, and controlled release of the cargo drug molecules by V-amylose. Besides, V-amylose presents characteristics of an ideal drug delivery system, such as biocompatibility, physiological benevolence, nonimmunogenicity, and biodegradability. The V-amylose polysaccharide chains fold into left-handed single helix comprising of six glucose units in each turn having a pitch height of 7.91-8.17 Å. These structural features of V-amylose differentiate it from the parent amylose polysaccharide and enable the accommodation and nanoencapsulation of a wide range of therapeutics in the former. The tightly packed helical structure of V-amylose provides extraordinary resistance toward digestion by amylase compared with the linear polysaccharides, which supports the application of V-amylose as controlled drug release systems. The activity of the amylase enzyme produced by salivary glands, pancreas, gastrointestinal tract, and gut microbiota on amylose-based drug delivery vehicles promote enzyme-sensitive controlled oral and colon-specific release of the encapsulated drug. The single helical V-amylose with hydrophobic core and hydrophilic periphery forms inclusion complexes that improve the absorption and permeation of drugs having a high clogP index. The present commentary highlights the distinguished features of V-amylose as an imminent drug delivery system | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a amylose | |
650 | 4 | |a controlled release | |
650 | 4 | |a encapsulation | |
650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
650 | 7 | |a Amylose |2 NLM | |
650 | 7 | |a 9005-82-7 |2 NLM | |
700 | 1 | |a Fatima, Rabab |e verfasserin |4 aut | |
700 | 1 | |a Sharma, Mousmee |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Drug development research |d 1993 |g 82(2021), 6 vom: 15. Sept., Seite 727-729 |w (DE-627)NLM081794991 |x 1098-2299 |7 nnns |
773 | 1 | 8 | |g volume:82 |g year:2021 |g number:6 |g day:15 |g month:09 |g pages:727-729 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/ddr.21804 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 82 |j 2021 |e 6 |b 15 |c 09 |h 727-729 |